Global Plasma Therapeutics Market 2015-2019

Global Plasma Therapeutics Market 2015-2019

About plasma and plasma therapeutics

Plasma, pale yellow in color, is the component of the blood. It acts as a medium of transportation for the blood cells and other components. It carries salts and enzymes along with water and also transports nutrients, hormones, and other substances to the different parts of the body. Plasma contains immunoglobulins, clotting factors, albumin, and other components that can be used for the treatment of various diseases. The separation of plasma from the blood is done by a process known as plasmapheresis. Plasma therapeutics are utilized in the treatment of rare, life-threatening, chronic, and genetic diseases, such as immune deficiencies, pulmonary disorders, neurological disorders, shock and trauma, liver cirrhosis, and infectious diseases such as tetanus, hepatitis, and rabies.

Technavio's analysts forecast the global plasma therapeutics market to grow at a CAGR of 12.10% over the period 2014-2019.

Covered in this report

The report covers the present scenario and the growth prospects of the global plasma therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded therapies derived from the various fractions of plasma such as albumin, immunoglobulins, coagulation factors, hyperimmune globulins, and A1PI.

Technavio's report, Global Plasma Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global plasma therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.Key regions

• Americas
• APAC
• EMEA

Key vendors

• Baxter
• CSL Behring
• Grifols Therapeutics
• Octapharma

Other prominent vendors

• Abeona Therapeutics
• ADMA Biologics
• Amag Pharmaceuticals
• Antares Pharma
• BioDelivery Sciences
• Bio Products Laboratory
• Biota Pharmaceuticals
• Biotest Pharmaceuticals
• China Biologic Products
• Depomed
• Emergent BioSolutions
• Ethicon
• Flamel Technologies
• Kamada
• Kedrion
• King Pharmaceuticals
• Nektar Therapeutics
• OMRIX Biopharmaceuticals
• ProMetic Life Sciences
• Rockwell Medical
• The Medicines
• ZymoGenetics

Key market driver

• Growing demand for IVIG therapies
• For a full, detailed list, view our report

Key market challenge

• High cost of therapy
• For a full, detailed list, view our report

Key market trend

• Patient assistance programs
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Press Release

Technavio Announces the Publication of its Research Report – Global Plasma Therapeutics Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Plasma Therapeutics Market: Baxter, CSL Behring, Grifols Therapeutics, and Octapharma

Other Prominent Vendors in the market are: Abeona Therapeutics, ADMA Biologics, Amag Pharmaceuticals, Antares Pharma, BioDelivery Sciences, Bio Products Laboratory, Biota Pharmaceuticals, Biotest Pharmaceuticals, China Biologic Products, Depomed, Emergent BioSolutions, Ethicon, Flamel Technologies, Kamada, Kedrion, King Pharmaceuticals, Nektar Therapeutics, OMRIX Biopharmaceuticals, ProMetic Life Sciences, Rockwell Medical, The Medicines, ZymoGenetics

Commenting on the report, an analyst from Technavio’s team said: “Patient assistance programs for plasma therapeutics are boosting the growth of the market. Vendors nowadays provide co-pay assistance to individuals who purchase plasma therapeutics.”

According to the report, IVIG is the largest segment of the plasma therapeutics market. IVIG is being increasingly used due to increases in the number of bleeding disorders, CIDP, and the global aging population. This has led to increased demand for IVIG therapeutics.



Further, the report states that the high cost of plasma therapeutics hinders market growth. Plasma protein therapies cost nearly four times more than other pharmaceutical medicines because of the use of expensive technologies in the manufacturing and processing of plasma-derived products.

Companies Mentioned

Baxter, CSL Behring, Grifols Therapeutics, Octapharma, Abeona Therapeutics, ADMA Biologics, Amag Pharmaceuticals, Antares Pharma, BioDelivery Sciences, Bio Products Laboratory, Biota Pharmaceuticals, Biotest Pharmaceuticals, China Biologic Products, Depomed, Emergent BioSolutions, Ethicon, Flamel Technologies, Kamada, Kedrion, King Pharmaceuticals, Nektar Therapeutics, OMRIX Biopharmaceuticals, ProMetic Life Sciences, Rockwell Medical, The Medicines, ZymoGenetics